Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGT007
- Development stage
- Phase 1
- Lead developer
- Biosyngen
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
BGT007 is a next-generation dual-target chimeric antigen receptor T-cell (CAR-T) therapy developed for the treatment of various solid tumors, particularly gastrointestinal and nasopharyngeal cancers. It consists of human T lymphocytes genetically engineered to express a CAR targeting two undisclosed tumor-associated antigens. The drug is designed to enhance immunostimulatory and antineoplastic activity by enabling the modified T cells to recognize and kill cancer cells expressing either or both target antigens. Its mechanism involves immunologic cytotoxicity and replacement of native T lymphocytes with engineered ones capable of targeted tumor cell destruction. Clinical development has focused on recurrent/metastatic refractory digestive tract tumors, nasopharyngeal carcinoma, pancreatic cancer, colorectal cancer, esophageal carcinoma, stomach cancer, and other gastrointestinal malignancies[1][3][4][5].
- Other names
- BGT007BGT-007BGT 007
Beyond the preview
Go deeper on BGT007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGT007.